The US Food and Drug Administration (FDA) has approved semaglutide (Ozempic, Novo Nordisk) as an adjunct to diet and exercise for the treatment of type 2 diabetes in adults.The long-acting glucagon-like peptide-1 (GLP-1) receptor agonist was approved in 0.5-mg and 1.0-mg doses, to be administered once weekly via a dedicated prefilled pen device. Semaglutide is now the seventh GLP-1 receptor agonist on the US market and the third dosed once weekly. However, data suggest it might be more effective than some of its competitors.